CRIS Share Price

Open 2.93 Change Price %
High 3.09 1 Day 0.14 4.76
Low 2.88 1 Week 0.04 1.32
Close 3.08 1 Month -0.07 -2.22
Volume 419716 1 Year 0.25 8.83
52 Week High 3.72
52 Week Low 1.25
CRIS Important Levels
Resistance 2 3.27
Resistance 1 3.19
Pivot 3.02
Support 1 2.97
Support 2 2.89
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Curis, Inc. (NASDAQ: CRIS)

CRIS Technical Analysis 3
As on 8th Dec 2016 CRIS Share Price closed @ 3.08 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.01 & Buy for SHORT-TERM with Stoploss of 2.92 we also expect STOCK to react on Following IMPORTANT LEVELS.
CRIS Target for December
1st Target up-side 3.68
2nd Target up-side 4.23
3rd Target up-side 4.78
1st Target down-side 2.12
2nd Target down-side 1.57
3rd Target down-side 1.02
CRIS Other Details
Segment EQ
Market Capital 288233760.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.curis.com
CRIS Address
CRIS
4 Maguire Road
Lexington, MA 02421
United States
Phone: 617-503-6500
Fax: 617-503-6501
Interactive Technical Analysis Chart Curis, Inc. ( CRIS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Curis, Inc.
CRIS Business Profile
Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).